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 Introduction 
 The overactive bladder (OAB) syndrome has a preva-
lence of 11.8% and is characterized by urgency, with or 
without urge incontinence and usually with frequency 
and nocturia  [1] . Men and women are equally affected 
with a high impact on quality of life, work productivity 
and sexual life  [2] . In addition, OAB is a high economic 
burden and the prevalence increases with age  [3] . If no 
neurogenic cause for the bladder dysfunction like Par-
kinson disease, spinal cord injuries, spinal cord stenosis 
or diabetes mellitus exists, the causative reason for the 
OAB  symptoms  often  remains unclear. In these cases, 
the OAB is called non-neurogenic or idiopathic. Standard 
treatment options for OAB are antimuscarinics and blad-
der training. However, in some patients antimuscarinic 
treatment fails, contraindications for antimuscarinics 
exist or the antimuscarinics trigger severe side effects. In 
the past, for these patients invasive surgery (mainly blad-
der augmentation) was the only available treatment op-
tion. Intradetrusor injection of botulinum toxin repre-
sents an alternative and minimally invasive treatment 
option for these patients with good results even after re-
peated injections  [4–9] . As of yet, botulinum toxin is not 
licensed for the use in OAB patients and the optimum 
dose for intradetrusor injections is not defined  [10] .
 In numerous studies, the efficacy of botulinum toxin 
in patients with idiopathic OAB was examined and 
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 Abstract 
 Objective: The aim of the study was a prospective assess-
ment of patient-reported side effects in an open-label study 
after intradetrusor botulinum toxin injections for idiopathic 
overactive bladder (OAB).  Patients and Methods: Botulinum 
toxin A injection was performed in 56 patients with idiopath-
ic OAB. Patients were followed up for 6 months concerning 
side effects and patients’ satisfaction.  Results: Different 
types of side effects were assessed such as dry mouth (19.6%), 
arm weakness (8.9%), eyelid weakness (8.9%), leg weakness 
(7.1%), torso weakness (5.4%), impaired vision (5.4%) and dys-
phagia (5.4%). In all cases, symptoms were mild and transient. 
Urological complications such as gross hematuria (17.9%), 
acute urinary retention (8.9%) and acute urinary tract infec-
tion (7.1%) were noticed. In all cases, acute urinary retention 
was transient and treated with temporary intermittent self-
catheterization. There was no statistically significant correla-
tion between dosage and observed side effects. Patients’ sat-
isfaction rate was high (71.4%).  Conclusion: Intradetrusor in-
jection of botulinum toxin was associated with a high rate of 
neurourological side effects. In general, side effects were 
transient, mild and did not require special treatment. 
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showed significant improvement of OAB symptoms  [6, 
11–15] . In most cases, the authors reported urological side 
effects or complications like urinary retention and uri-
nary tract infection (UTI). However, data are lacking re-
garding systemic side effects. Only a few studies analyzed 
this complication  [11, 15–17] , and no quantitative data are 
given. Therefore, the aim of the present study was to assess 
side effects after intradetrusor injections of botulinum 
toxin type A in patients with refractory idiopathic OAB.
 Patients and Methods 
 Between June 2007 and February 2009, 56 consecutive patients 
with refractory idiopathic OAB were treated with botulinum tox-
in type A in a prospective clinical study. Botulinum toxin was 
injected at 20 sites in the detrusor vesicae. All patients received 
antibiotics for 3 days postoperatively. We used Dysport  500 IU 
(Ipsen Ltd) or Botox  100, 150 and 200 IU (Allergan Ltd).
 Preoperatively, urodynamic assessment, ultrasound for resid-
ual urine and urine analysis were performed. Patients with neu-
rogenic OAB, residual urine  1 50 ml and patients with acute uri-
nary infections were excluded from this study. Further, patients 
with less than two failed treatment trials with antimuscarinics at 
therapeutic dosage for a minimum of 6 months were excluded. 
However, we included patients who were not able to take antimus-
carinics because of severe side effects or contraindications for an-
timuscarinics. Patient age was 41–87 years (mean 65). 41 patients 
were female (73.2%) and 15 male (26.8%).
 Postoperatively, patients had ultrasound for residual urine be-
fore discharge. Patients with acute postoperative urinary reten-
tion (residual urine  1 100 ml) were trained in intermittent self-
catheterization (ISC). ISC was stopped when residual urine was 
 ! 100 ml. One week after discharge, urinalysis was performed to 
rule out acute urinary infection. Ultrasound for residual urine 
was performed at 1 week, 6 weeks, 3 and 6 months postoperative-
ly. In addition, patients were interviewed concerning side effects 
of botulinum toxin: gross hematuria, dry mouth, dysphagia, 
speech problems, impaired vision, eyelid weakness, arm weak-
ness, leg weakness, torso weakness and combined weakness of the 
whole body. After 6 months, patients were interviewed concern-
ing overall treatment satisfaction.
 Statistical Analysis 
 p values  ! 0.05 were considered significant. All statistical anal-
yses were performed using Statistica for Windows, release 8 (Stat-
Soft, Tulsa, Okla., USA). The   2 test was used to analyze the influ-
ence of various botulinum toxin doses on side effects.
 Results 
 At least one side effect occurred in 53.6% of the pa-
tients ( fig. 1 ).
 Acute Postoperative Urinary Retention 
 In 5 patients (8.9%) a residual urine of  1 100 ml was 
detected. These patients performed ISC for a mean of 41 
days (range 6–56). There was no statistically significant 
correlation between postoperative residual urine and the 
botulinum toxin dose injected (p = 0.292).
 Postoperative Gross Hematuria 
 In 10 patients (17.9%), gross hematuria occurred after 
injection and disappeared in all cases without further 
treatment after at least 7 days. In all cases, hematuria was 
only mild and patients needed no further investigation or 
treatment. There was no statistically significant correla-
tion between postoperative gross hematuria and the in-
jected dose (p = 0.074).
 Postoperative Acute Urinary Tract Infection 
 Urinanalysis 1 week after botulinum toxin injection 
showed symptomatic UTI in 4 patients (7.1%) and was 
treated with oral antibiotics. No patient showed recurrent 
infections. There was no statistically significant correla-
tion between postoperative acute UTI and the injected 
dose (p = 0.861).
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 Fig. 1. Side effects correlated to the amount of botulinum toxin A 
injected. 
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 Dry Mouth, Dysphagia and Speech Disorders 
 Eleven patients (19.6%) complained of a dry mouth 
and 3 patients (5.4%) had dysphagia additionally due to 
their dry mouth (27.3% of the patients with dry mouth). 
There were no cases of speech disorders. In all cases, the 
symptoms were mild and the patients handled the dry 
mouth with an increased intake of daily fluid. The dry 
mouth disappeared after a mean of 19 days (range 7–31). 
There was no statistically significant correlation between 
dry mouth (p = 0.117) or dysphagia (p = 0.217) and the 
injected dose.
 Impaired Vision and Eyelid Weakness 
 Three patients (5.4%) complained of impaired vision 
and 5 patients (8.9%) of eyelid weakness. In all cases, the 
symptoms were mild and patients needed no further in-
vestigation or treatment. Impaired vision disappeared af-
ter a mean of 5 days (range 3–14) and eyelid weakness 
after a mean of 17 days (range 3–41). There was no statis-
tically significant correlation between impaired vision 
(p = 0.238) or eyelid weakness (p = 0.359) and the inject-
ed dose.
 Arm, Leg, Torso and Combined Weakness of the 
Whole Body 
 Five patients (8.9%) complained of arm weakness for a 
mean of 45 days (range 15–68). Four patients (7.1%) com-
plained of leg weakness for a mean of 41 days (range 12–
60). Three patients (5.4%) complained of torso weakness 
for a mean of 21 days (range 7–35). There was no com-
bined muscle weakness of the whole body. Symptoms 
were mild in all cases. Patients were presented to a neu-
rologist, but no special treatment was necessary. There 
was no statistically significant correlation between mus-
cle weakness and the injected dose (arm: p = 0.728, leg: 
p = 0.544, torso: p = 0.954).
 Satisfaction 
 71.4% of the patients were satisfied or very satisfied 
with the injection of botulinum toxin ( fig. 2 ). Overall, pa-
tients with side effects had a lower satisfaction rate than 
patients without side effects.
 Discussion 
 In the present study, 56 patients with idiopathic OAB 
syndrome were treated with intradetrusor injection of 
botulinum toxin type A. 53.6% of the patients presented 
with at least one side effect. Main side effects were dry 
mouth (19.6%), gross hematuria (17.9%), acute postopera-
tive urinary retention (8.9%), weakness of the arms (8.9%) 
and eyelid weakness (8.9%). Postoperative acute UTI oc-
curred in 7.1% of the cases. In all cases except acute uri-
nary retention and infection, symptoms were mild, tran-
sient and no further investigation or treatment was nec-
essary. Acute urinary retention was transient in all cases 
and was treated with ISC. There was no statistically sig-
nificant correlation between botulinum toxin doses and 
side effects. Patients’ satisfaction rate was high (71.4% sat-
isfied or very satisfied).
 The UTI rate varies strongly regarding different series 
from 6.5% up to 44%  [18] . In comparison, we found a 
comparably low rate of postoperative acute UTIs (7.1%). 
This may be due to antibiotic prophylaxis during surgery 
and the continuation of oral antibiotics for 3 days in our 
series which probably decreased the rate of UTIs diag-
nosed.
 Given the mechanism of action of botulinum toxin, it 
is not surprising that some patients experience urinary 
retention. However, analysis of data concerning urinary 
retention and residual urine represents a difficult prob-
lem. Definition of acute urinary retention and the indica-
tion for ISC varies from study to study. In our series, pa-
tients with residual urine  1 100 ml were trained in ISC. 
Three patients (2  ! 500 IU Dysport  , 1  ! 200 IU Bo-
tox  ) were not able to empty the bladder spontaneously 
and required intermittent catheterization at 3 weeks. The 
remaining 2 subjects experienced postvoid residual urine 
values greater than 20% of their bladder capacity at the 
3-week evaluation. These complications are consistent 
with those reported by other authors. Flynn et al.  [5] mea-
sured in 26% residual urine of  6 200 ml in a placebo-
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 Fig. 2. Patients’ satisfaction 6 months after injection of botulinum 
toxin. VS = Very satisfied; S = satisfied; MS = moderately satisfied; 
NS = not satisfied. 
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controlled study. Popat et al.  [17] reported in 19.3% re-
sidual urine necessitating ISC after injection of 200 IU 
Botox  . In another placebo-controlled study, residual 
urine increased in 43% after injection of 200 IU botuli-
num toxin  [11] . In contrast, the placebo group of this se-
ries showed no increase of residual urine.
 Overall, the risk of developing significant residual 
urine or acute urinary retention seems to increase with 
higher doses of injected botulinum toxin  [19] . In addi-
tion, patients with neurogenic OAB suffer more often 
from urinary retention after botulinum A injections into 
the bladder  [17] . However, we were not able to show a dose 
relation regarding postoperative urinary retention. This 
may be due to the fact that we did not inject high botuli-
num doses and excluded patients with neurogenic OAB 
from this series.
 There are only limited data available concerning neu-
rological side effects. Jeffery et al.  [16] report on 1 of 25 
patients (4%) who suffered from general muscle weakness 
after botulinum toxin injection. Sahai et al.  [15] investi-
gated muscle weakness after botulinum toxin injection in 
the bladder and noticed no generalized muscle weakness 
necessitating admission. However, this study does not 
mention mild muscle weakness. Brubaker et al.  [11] re-
port serious adverse events, including non-urinary infec-
tion, cardiovascular, neurological and musculoskeletal 
system injury in the botulinum toxin group (3 of 28 pa-
tients) as well as in the placebo group (2 of 15 patients). In 
addition, 6 unexpected adverse events including gastro-
intestinal complications occurred in the botulinum toxin 
group. A detailed work-up of these adverse events is miss-
ing.
 Our data are limited by the fact that the assessment of 
non-urological side effects was based on patient ques-
tionnaires and that there is no placebo arm. This mea-
surement is subjective and might induce bias. Another 
limitation is the relatively small number of patients. How-
ever, most series included less cases and only a few studies 
report on more than 100 patients  [6, 20, 21] .
 Overall, patients reported a surprisingly high rate of 
neurological side effects which were mild, transient and 
did not require further treatment. The patients described 
here, who suffered from muscle weakness after treatment 
for bladder overactivity with injection of botulinum tox-
in in the detrusor muscles, received different types of bot-
ulinum toxin. The pathogenesis of side effects in our pa-
tients remains unclear. The bladder wall, especially be-
tween trabeculation bars, may have been too thin so that 
diffusion perivesically occurred together with a limita-
tion of the local effect.
 Hematological spread by inadvertent delivery of the 
toxin into a blood vessel may be another reason. How-
ever, we did not find gross hematuria in these patients. 
Diffusion of botulinum toxin within the injected muscle 
and  into  adjacent  muscles has been well documented 
 [22] . Retrograde axonal transport represents another 
possibility  [23] . Weakness or pathological EMG changes 
in muscles distal to the injection site have been reported 
in different applications  [24] .
 A particular product or batch of the toxin cannot be 
blamed as our patients received toxins from different 
batches and manufacturers. The frequency of side effects 
did not differ significantly between Dysport  and Bo-
tox  , although data showed a tendency towards more side 
effects after treatment with 200 IU Botox  . The total dos-
es used in our patients were within the range generally 
recommended. Although none of our patients showing 
side effects received repeated injections, it may be specu-
lated that repeated treatments may have an impact on 
toxin binding and diffusion, because functional recovery 
of poisoned cells is achieved by means of sprouting of new 
motor axon terminals. It is conceivable that botulinum 
toxin binding is impaired and uptake of botulinum toxin 
after repeated injections could take place at some dis-
tance from the injection site. The safety of repeated injec-
tions is rarely or not described. To minimize the risk of 
immune resistance and response as much as possible, it 
is advisable to wait at least 3 months between injections, 
and to choose the lowest dose that will achieve the desired 
effect  [8] .
Conclusion
 We have described a high rate of neurourological side 
effects after intradetrusor botulinum toxin injections. 
The cause is most likely presynaptic inhibition due to sys-
temic spread of the toxin. Which patients have a particu-
lar risk of developing this complication remains to be de-
termined. Caution is needed in patients with impaired 
neurotransmission such as with myasthenia gravis, or 
taking drugs that may interfere with neurotransmission 
 [24] . There is a definite need for close observation of gen-
eral effects and for studies on the optimal dose and the 
optimal injection technique in this type of treatment. 
Meanwhile, patients should be warned that temporary 
general side effects may occur. 
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